logo-loader
Lancor Scientific

Tumour Trace device 'just makes sense' - Lancor's chief medical officer

Lancor Scientific's chief operating officer Gopal Rao and chief medical officer Roland Schlesinger discuss with Proactive Investors some of the upcoming milestones for their Tumour Trace technology.

Roland Schlesinger's a specialist in health technology assessment - essentially analysing pharmaceuticals or medical technologies for efficiency and efficacy.

''The great thing about the technology is that we're looking for  a quantifiable biomarker in the tissue - the hugely exciting thing about that is we're looking for a primary cancer, not a metastatic one, which means we're not catching it late we're very much catching it both early and even pre-early'', Rao says.

''We are absolutely able to reach an accuracy level of 98% definitely .... compared to others that are around 73-78%%'', Schlesinger says.

He adds: ''Also the time is very important - most procedures take days .. however with us we have results in less than three minutes''.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lancor Scientific named herein, including the promotion by the Company of Lancor Scientific in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Lancor Scientific to have its screening device approved for six cancers by March

Lancor Scientific's Roland Schlesinger updates Proactive London's Andrew Scott on latest developments with their cancer screening device. He says they've already got one cancer device approved with five more soon to follow. ''We're in the process of moving towards mass production...

on 22/5/19

2 min read